Reported by Zhang Yu-ling from Taipei

Premier William Lai (賴清德) gave the Executive Yuan’s final approval yesterday to the Draft Act for Regenerative Medicine Management. Deputy Minister of Health and Welfare Ho Chi-kung (何啟功) said that the government will grant conditional marketing licenses to regenerative medicines that have completed phase II clinical trials. Such licenses will be valid for not more than 5 years and are only issued to medicines targeting acute illnesses and diseases with no other treatment options.

【2018-10-19/China Times】